These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34898537)

  • 1. Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time.
    Ataikiru O; Abdelsalam M; Avileli M; Hynes T
    Curr Oncol; 2021 Oct; 28(6):4291-4297. PubMed ID: 34898537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.
    Ni YC; Zhao JG; Zhang MN; Zhang YJ; Yang ZY; Chen N; Chen JR; Shen PF; Sun GX; Zhang XM; Li YH; Zeng H
    Asian J Androl; 2022; 24(2):154-160. PubMed ID: 34380864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone.
    Roviello G; Petrioli R; Bonetta A; Conca R; Rodriquenz MG; Aieta M
    Invest New Drugs; 2018 Dec; 36(6):1110-1115. PubMed ID: 30345466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone.
    Yang Z; Ni Y; Zhao D; Zhang Y; Wang J; Jiang L; Chen D; Wu Z; Wang Y; He L; Shi Y; Zhou F; Zeng H; Li Y
    BMC Cancer; 2021 Aug; 21(1):919. PubMed ID: 34388965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
    Fang WY; Wang PF; Fan YC; Shih HJ
    Urol Int; 2021; 105(5-6):380-385. PubMed ID: 32791510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
    Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid switch after progression on abiraterone acetate plus prednisone.
    Roviello G; Sobhani N; Corona SP; D'Angelo A
    Int J Clin Oncol; 2020 Feb; 25(2):240-246. PubMed ID: 31705219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
    BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
    Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
    Lorente D; Omlin A; Ferraldeschi R; Pezaro C; Perez R; Mateo J; Altavilla A; Zafeirou Z; Tunariu N; Parker C; Dearnaley D; Gillessen S; de Bono J; Attard G
    Br J Cancer; 2014 Dec; 111(12):2248-53. PubMed ID: 25314055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.
    Xiong X; Qiu S; Yi X; Xu H; Liao D; Lei H; Bai S; Peng G; Ai J; Yang L
    Urol Oncol; 2021 Nov; 39(11):754-763. PubMed ID: 34330654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
    Duarte C; Jimeno A; Kessler ER
    Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
    Gill D; Gaston D; Bailey E; Hahn A; Gupta S; Batten J; Alex A; Boucher K; Stenehjem D; Agarwal N
    Clin Genitourin Cancer; 2017 Aug; 15(4):e599-e602. PubMed ID: 28131750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
    Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.